520-85-4
520-85-4
Chemical Structure
Medroxyprogesterone
Synonym(s): 17α-Hydroxy-6α-methylprogesterone; U8840
- No. CAS: 520-85-4
- Formula:C22H32O3
- Molecular Weight:344.49
IUPAC Name: (6S,8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one
InChIKey: FRQMUZJSZHZSGN-HBNHAYAOSA-N
SMILES: C[C@@]1([C@@]2(O)C(C)=O)[C@](CC2)([H])[C@@](C[C@H](C)C3=CC4=O)([H])[C@]([C@]3(CC4)C)([H])CC1
Biological Activity: Medroxyprogesterone (17α-Hydroxy-6α-methylprogesterone) is a synthetic human variant of progesterone that is a progesterone receptor agonist with oral activity. Medroxyprogesterone can induce cell proliferation through the PI3K/Akt signaling pathway. Medroxyprogesterone has an inhibitory effect on atherosclerosis in mice. The progesterone agonist activity of Medroxyprogesterone is less effective than Medroxyprogesterone acetate (HY-B0469)[1][2][3][4].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Medroxyprogesterone | 98.82% | Medroxyprogesterone (17α-Hydroxy-6α-methylprogesterone) is a synthetic human variant of progesterone that is a progesterone receptor agonist with oral activity. Medroxyprogesterone can induce cell proliferation through the PI3K/Akt signaling pathway. Medroxyprogesterone has an inhibitory effect on atherosclerosis in mice. The progesterone agonist activity of Medroxyprogesterone is less effective than Medroxyprogesterone acetate (HY-B0469). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Medroxyprogesterone (Standard) | 99.10% | Medroxyprogesterone (Standard) is the analytical standard of Medroxyprogesterone. This product is intended for research and analytical applications. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Medroxyprogesterone-d7 | Medroxyprogesterone-d7 is deuterium labeled Medroxyprogesterone. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Medroxyprogesterone-d3 | Medroxyprogesterone-d3 is the deuterium labeled Medroxyprogesterone. Medroxyprogesterone is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
21-Deoxycortisol | 99.49% | 21-Deoxycortisol is an adrenal-specific C21 steroid that accumulates via alternative pathways due to 21-hydroxylase (CYP21A2/P450c21) deficiency. 21-Deoxycortisol serves as a sensitive and specific biomarker for steroid 21-hydroxylase deficiency (21OHD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cortodoxone | 98.58% | Cortodoxone (11-Deoxycortisol; cortexolone) is a glucocorticoid steroid hormone and also is a glucocorticoid antagonist. Cortodoxone increases tryptophan oxygenase (TO) activity and induces the secretion of corticosterone. Cortodoxone regulates T cell proliferation and activation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Medroxyprogesterone acetate | 99.88% | Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
17α-Hydroxyprogesterone | 99.63% | 17α-Hydroxyprogesterone is a steroid hormone. 17α-Hydroxyprogesterone induces ovarian growth and yolk production in female crabs and increases blood pressure in sheep. 17α-Hydroxyprogesterone is mainly used in research related to crustacean reproduction and animal hypertension. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
17α-Hydroxyprogesterone-13C3 | 17α-Hydroxyprogesterone-13C3 is the 13C-labeled 17α-Hydroxyprogesterone. 17α-Hydroxyprogesterone (17-Hydroxyprogesterone) is an endogenous progestogen as well as chemical intermediate in the biosynthesis of other steroid hormones, including the corticosteroids and the androgens and the estrogens. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Megestrol | 99.44% | Megestrol is an orally active glucocorticoid and progesterone receptor agonist. Megestrol can alleviate anorexia, cachexia or unexplained significant weight loss associated with acquired immunodeficiency syndrome (AIDS). Megestrol may cause manifestations similar to those of glucocorticoids and increase the risk of mental disorders. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Medroxyprogesterone acetate impurity 2 | Medroxyprogesterone acetate impurity 2 is an impurity of Medroxyprogesterone acetate. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
21-Deoxy cortisone | 99.5% | 21-Deoxycortisone (21-Desoxycortisone; NSC 38722) is an endogenous C21 pregnane steroid metabolite. 21-Deoxycortisone is a substrate for 21-hydroxylation in calf adrenal glands and can be converted to Cortisone (HY-17461). 21-Deoxycortisone can be used for metabolism-related research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Methylprednisolone impurity 5 | Methylprednisolone impurity 5 is an impurity of Methylprednisolone. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Saitoh M, et al. Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology. 2005 Nov;146(11):4917-25. [Content Brief]
- [2]. Ito F, et al. Medroxyprogesterone acetate enhances monocyte-endothelial interaction under flow conditions by stimulating the expression of cell adhesion molecules. J Clin Endocrinol Metab. 2014 Jun;99(6):2188-97. [Content Brief]
- [3]. Freudenberger T, et al. Differential effects of medroxyprogesterone acetate on thrombosis and atherosclerosis in mice. Br J Pharmacol. 2009 Dec;158(8):1951-60. [Content Brief]
- [4]. Yusop SNW, et al. Medroxyprogesterone derivatives from microbial transformation as anti-proliferative agents and acetylcholineterase inhibitors (combined in vitro and in silico approaches). Steroids. 2020 Dec;164:108735. [Content Brief]
